Hongwei Yao | Gastrointestinal Pharmacology | Best Researcher Award

Prof. Hongwei Yao, capital medical university Affiliated Beijing Friendship Hospital, China

Prof. Dr. Hongwei Yao 🧑‍⚕️ is a renowned gastrointestinal surgeon with over 20 years of experience in diagnosing and treating GI tumors. 💉 He excels in laparoscopic and transanal endoscopic microsurgery (TEM) 🩺 and has led multiple research studies, authoring 100+ academic papers 📚—90+ focused on colorectal surgery. 🧬 He is the lead translator of Standard Laparoscopic Surgery for Upper GI Tract and co-translator of the national textbook Colorectal and Anal Surgery. 🔬 Prof. Yao holds two utility model patents for surgical innovations and continues to pioneer breakthroughs in colorectal cancer treatment. 🧠 His work bridges clinical expertise and cutting-edge research.

Publication Profile

Orcid

Education

Prof. Dr. Hongwei Yao 🧑‍⚕️ is a distinguished gastrointestinal surgeon with over 20 years of clinical excellence in diagnosing and treating GI tumors 🧬. An expert in advanced surgical techniques such as laparoscopic surgery and transanal endoscopic microsurgery (TEM) 🔍, he is known for handling complex gastrointestinal procedures with precision. He has led numerous research projects and authored more than 100 academic papers 📚, with over 90 focusing on colorectal surgery. He served as lead translator of Standard Laparoscopic Surgery for Upper GI Tract 📘 and co-translator of Colorectal and Anal Surgery 📖. Prof. Yao also holds two utility model patents .

Editorial Appointments

Prof. Hongwei Yao 🧑‍⚕️ holds esteemed editorial roles in several leading medical journals. Since December 2019, he has served as Associate Editor for the Diseases of the Colon & Rectum journal 🧻, which is indexed in SSCI. Additionally, he has been a dedicated Editorial Board Member for the Chinese Journal of Inflammatory Bowel Diseases 💢 since February 2017, and for the Chinese Journal of Digestive Surgery 🩺 since July 2021, both indexed in CSCD and CSTPCD. These appointments reflect his profound expertise in gastrointestinal surgery and commitment to advancing medical research and literature 📚.

Research Focus

Prof. Hongwei Yao 🧑‍⚕️ focuses his groundbreaking research on colorectal cancer, gastrointestinal surgery, and translational oncology 🧬. His core interest lies in neoadjuvant therapies combining chemoradiation with immunotherapy (especially PD-1/PD-L1 blockade) for treating locally advanced rectal cancer 🎯. His innovative studies explore gut microbiota, nanomedicine, biospectroscopy, and surgical optimization to personalize cancer care 🧪. He also advances wound healing and stem cell therapies for post-surgical recovery 🩹. Through high-impact publications and clinical trials, Prof. Yao contributes to redefining standards in cancer diagnostics, surgical margins, and immune modulation in GI tumors ⚕️.

Publication Top Notes

Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial

Opportunities and challenges of indocyanine green in gastrointestinal cancers for intraoperative and nano-medicine application

Opportunities and challenges of nanomaterials in wound healing: Advances, mechanisms, and perspectives

Enhancing thromboprophylaxis after colorectal cancer surgery in China: Bridging the gap between evidence and implementation through pathway optimization

Exploring causal correlations between circulating levels of cytokines and colorectal cancer risk: A Mendelian randomization analysis

Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer

Definition and grading of anastomotic leakage following right hemicolectomy

Perfusion outcomes with near-infrared indocyanine green imaging system in laparoscopic total mesorectal excision for mid-rectal or low-rectal cancer (POSTER): a study protocol

The Role and Prospects of Mesenchymal Stem Cells in Skin Repair and Regeneration

Shuwei Zhou | Gastrointestinal Pharmacology | Best Researcher Award

Ms. Shuwei Zhou, Southeast University Zhongda Hospital, China

🔬 Dr. Shuwei Zhou is a distinguished researcher specializing in imaging and nuclear medicine at Zhongda Hospital, Southeast University, China. 🏥 She holds a Ph.D. in Imaging and Nuclear Medicine from Southeast University and a B.A. & Master’s from Hunan University of Chinese Medicine. 🎓 Dr. Zhou has authored numerous high-impact SCI publications 📑 focusing on HCC, LI-RADS, MRI diagnostics, and treatment response. Her contributions include 4 national research projects and 2 patents. 🏆 As a leading expert in radiology and medical imaging, her work advances diagnostic accuracy and patient care in oncology and musculoskeletal disorders. ⚕️✨

Publication Profile

Scopus

Education

Ms. Shuwei Zhou 🎓 has showcased outstanding academic excellence, earning a Ph.D. in Imaging and Nuclear Medicine from the School of Medicine at Southeast University 🏥. Her strong foundation in the field began at Hunan University of Chinese Medicine, where she completed her B.A. and Master’s degree, ranking 1st out of 159 students 🏆. With expertise in molecular and functional imaging, interventional radiology, and pathology 🔬, she has developed a deep understanding of advanced medical diagnostics. Her dedication to research and innovation continues to shape the future of nuclear medicine and imaging technology. 🚀

Experience

Ms. Shuwei Zhou 🔬 has made significant research contributions, publishing in esteemed journals like the American Journal of Roentgenology, Abdominal Radiology, and Frontiers in Immunology 📚. As the first author, she has led groundbreaking studies on MRI contrast agents, diagnostic performance, and treatment response in hepatocellular carcinoma (HCC) 🏥. Her interdisciplinary expertise extends to osteoporosis prediction, the role of gut microbiota in inflammatory bowel disease, and dual-energy CT for bone mineral density 🦴. Through her innovative research, she continues to advance medical imaging and diagnostic precision, making a lasting impact on the field of nuclear medicine. 🚀

Awards

Ms. Shuwei Zhou 🎓 is a distinguished researcher whose impressive portfolio includes first-author contributions in high-impact journals, leadership in scientific projects, and remarkable interdisciplinary expertise 🔬. Her groundbreaking work in imaging and nuclear medicine, particularly in hepatocellular carcinoma research and diagnostic imaging techniques 🏥, has significantly advanced the field. With a strong commitment to innovation and precision in medical diagnostics, she continues to push the boundaries of research. Her achievements make her a highly deserving candidate for the Best Researcher Award 🏆, recognizing her invaluable contributions to the future of medical imaging and nuclear medicine. 🚀

Research Focus

Shuwei Zhou’s research primarily focuses on medical imaging 🏥📡 and oncology, with a particular emphasis on hepatocellular carcinoma (HCC) 🏨🧬 and non-radiation treatment response assessment. She is actively involved in the development of diagnostic algorithms 📊🔍, such as the LI-RADS Nonradiation Treatment Response Algorithm, and predictive models like the TRACE Model, which help evaluate the effectiveness of transarterial chemoembolization (TACE) 💉⚕️ in patients with unresectable liver cancer. Her contributions aim to enhance precision medicine 🎯 and optimize clinical decision-making for better patient outcomes.

Publication Top Notes

LI-RADS Nonradiation Treatment Response Algorithm Version 2024: Diagnostic Performance and Impact of Ancillary Features

TRACE Model: Predicting Treatment Response to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma